Back to top
more

Pacira BioSciences (PCRX)

(Delayed Data from NSDQ)

$16.57 USD

16.57
466,978

-0.03 (-0.18%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $16.58 +0.01 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ASRT or PCRX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ASRT vs. PCRX: Which Stock Is the Better Value Option?

Pacira's (PCRX) Exparel Meets Key Goals in C-Section Study

by Zacks Equity Research

Pacira's (PCRX) phase IV CHOICE study on its lead drug Exparel in patients undergoing Cesarean section attains the primary as well as key secondary endpoints.

Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study

by Zacks Equity Research

Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.

ASRT vs. PCRX: Which Stock Is the Better Value Option?

by Zacks Equity Research

ASRT vs. PCRX: Which Stock Is the Better Value Option?

Pacira's Late-Stage Study on Exparel Label Expansion Positive

by Zacks Equity Research

Pacira (PCRX) releases positive top-line data from its phase III PLAY study evaluating the pharmacokinetics and safety of Exparel in two patient groups.

Pacira's Exparel Spurs Growth, Exclusive Reliance a Concern

by Zacks Equity Research

Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging. However, sole dependence on the drug is a constant worry.

ASRT vs. PCRX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ASRT vs. PCRX: Which Stock Is the Better Value Option?

Pacira (PCRX) Up 7.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Pacira's (PCRX) third-quarter results reflect an earnings beat while revenues almost match estimates. Exparel drives year-over-year growth.

Pacira (PCRX) Q3 Earnings Surpass Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of 41.18% and -0.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Pacira (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pacira (PCRX) Down 15.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ASRT vs. PCRX: Which Stock Is the Better Value Option?

by Zacks Equity Research

ASRT vs. PCRX: Which Stock Is the Better Value Option?

Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Pacira (PCRX) rides high on both earnings and revenue beat in the second quarter of 2019. Moreover, Exparel drives year-over-year growth.

Pacira (PCRX) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of 20.59% and 2.80%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pacira (PCRX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pacira Gets EMA Acceptance for Pain Management Drug Exparel

by Zacks Equity Research

The EMA authorizes Pacira's (PCRX) marketing application for Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.

JAZZ or PCRX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

JAZZ vs. PCRX: Which Stock Is the Better Value Option?

Why Is Pacira (PCRX) Down 7.2% Since Last Earnings Report?

by Zacks Equity Research

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cara Shares Up on Positive Phase III Data for Itchiness Drug

by Zacks Equity Research

Cara (CARA) reports positive top-line data from phase III study of Korsuva injection in hemodialysis patients with moderate-to-severe chronic kidney disease-related pruritus.

JAZZ vs. PCRX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

JAZZ vs. PCRX: Which Stock Is the Better Value Option?

Pacira (PCRX) Misses Q1 Earnings Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of -8.33% and 0.28%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Why the Earnings Surprise Streak Could Continue for Pacira (PCRX)

by Zacks Equity Research

Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Pacira (PCRX) to Report Q1 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Pacira (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.